本报讯(记者曹琦)2月28日，江西金达莱环保股份有限公司(以下简称"金达莱")披露2025年度业绩快报， 公布公司全年经营核心数据。 报告显示，受市场环境变化及公司风险管控策略调整影响，公司营收、利润同比出现阶段性下滑，但财 务状况整体保持良性，同时在核心技术突破、标杆项目打造及新兴赛道布局上持续发力，为长期可持续 发展注入强劲动力，凸显专精特新企业的发展韧性。 核心业绩数据方面，业绩快报显示，2025年公司实现营业总收入3.38亿元，较上年同期的4.09亿元下降 17.29%；归属于母公司所有者的净利润9600.75万元，同比下降29.84%；归属于母公司所有者的扣除非 经常性损益的净利润7205.83万元，同比降幅达43.41%。基本每股收益为0.3479元，同比下降29.83%； 加权平均净资产收益率为3.04%，较上年同期下降1.30个百分点，核心盈利指标虽有下滑，但整体保持 盈利水平。 对于业绩变动的核心原因，金达莱在业绩快报中明确表示，报告期内公司面对复杂的行业市场环境，主 动强化项目质量筛选与过程风险管控，优先保障项目品质和财务安全，由此导致营收及利润出现阶段性 下滑。此外，营业利润及扣非归母净 ...

格隆汇2月27日丨金达莱(688057.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入3.38亿 元、归属于母公司所有者的净利润9600.75万元、归属于母公司所有者的扣除非经常性损益的净利润 7205.83万元，分别较上年同期下降17.29%、29.84%、43.41%，主要原因系面对当前市场环境，公司强 化项目质量筛选与过程风险管控，以保障项目品质和财务安全。整体来看，近年来公司财务状况始终保 持良性健康，资产负债结构良好，为公司可持续发展奠定了坚实基础。 ...

格隆汇2月27日丨金达莱(688057.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入3.38亿 元、归属于母公司所有者的净利润9600.75万元、归属于母公司所有者的扣除非经常性损益的净利润 7205.83万元，分别较上年同期下降17.29%、29.84%、43.41%，主要原因系面对当前市场环境，公司强 化项目质量筛选与过程风险管控，以保障项目品质和财务安全。整体来看，近年来公司财务状况始终保 持良性健康，资产负债结构良好，为公司可持续发展奠定了坚实基础。 ...

证券代码：688057 证券简称：金达莱 公告编号：2026-003 江西金达莱环保股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以江西金达莱环保股份有限公司（以下简称"公司"）2025 年年 度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 338,291,229.00 | 409,015,844.91 | -17.29 | | 营业利润 | 97,419,481.49 | 146,642,265.83 | -33.57 | | 利润总额 | 110,275,798.68 | 150,278,335.63 | -26.62 | | 归属于母公司所有者的 | 96,007,547.89 | 136,83 ...

金达莱发布业绩快报，2025年度公司实现营业总收入3.38亿元，同比下降17.29%；净利润9600.75万 元，同比下降29.84%。报告期内，公司聚焦水环境治理主业，坚持"技术引领、质量优先"的发展策略， 以核心技术优势打造标杆项目。由公司承建的"瑞昌市城西30,000m³/d污水处理厂"项目被中国环境保护 产业协会评为"2025年生态环境保护典型工程"，核心技术入选国家工信部第一批"先进适用技术名单"。 ...

Group 1 - The company, Jiangxi Jindalai Environmental Protection Co., Ltd., has approved an external investment plan to invest in Yunnan Jici Medical Technology Co., Ltd. [2][3] - The investment will be executed in three phases, with a total investment of RMB 150 million in the first phase, followed by RMB 50 million in the second phase, and the remaining funds after obtaining new drug clinical research approval [3][4] - The company aims to establish a concerted action relationship with Hu Min to jointly control Jici Medical in major decisions [3][4] Group 2 - The changes in the investment plan are expected to enhance the company's risk resistance and align with its long-term strategic development, without adversely affecting daily operations [5] - The investment is sourced from the company's own funds, which will not impose significant short-term cash flow pressure [8] - The company acknowledges the uncertainties and risks associated with drug development, including potential delays in clinical trials and regulatory approvals [9][10]

证券代码：688057 证券简称：金达莱 公告编号：2026-002 江西金达莱环保股份有限公司对外投资进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 投资标的名称 | 云南济慈医疗科技有限公司（以下简称"济慈医疗"） | | | --- | --- | --- | | 投资金额（万元） | 28,000 | | | 投资进展情况 | 完成 √交易要素变更 | 终止 | | 特别风险提示（如有） | 济慈医疗实际经营中可能受宏观经济、行业环境、市场变 | | | | 化等因素的影响，存在一定经营风险、财务风险、研发风险、 | | | | 政策风险等，未来业绩及收益仍存在不确定性。公司将密切关 | | | | 注投资事项的后续进展，积极防范和化解可能面临的各类风 | | | | 险，并按要求及时履行信息披露义务。敬请广大投资者谨慎决 | | | | 策，注意投资风险。 | | 一、对外投资基本情况 江西金达莱环保股份有限公司（以下简称"公司"）于2025年12月19日召开 第五届董事会第十一 ...

Core Viewpoint - The company plans to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., with changes in investment elements [1] Investment Details - The investment will be made in three phases: 150 million yuan upon completion of business registration, 50 million yuan after obtaining IIT permission, and the remaining amount after IND approval [1] - The board of directors has approved the aforementioned matters [1] Agreement and Risks - The company intends to reach a concerted action agreement with Hu Min [1] - Jici Medical faces operational, financial, research and development, and policy risks, leading to uncertainties in future performance and returns [1]

Group 1 - The stock price of Jindalai (688057) closed at 12.65 yuan on January 9, 2026, reflecting a 3.52% increase from the previous week's price of 12.22 yuan [1] - The highest intraday price for Jindalai on January 9 was 12.71 yuan, while the lowest intraday price on January 5 was 12.23 yuan [1] - Jindalai's current total market capitalization is 3.491 billion yuan, ranking 70th out of 106 in the environmental governance sector and 4329th out of 5182 in the A-share market [1] Group 2 - The company plans to invest 280 million yuan in Jici Medical, acquiring a 34.00% stake, focusing on autologous cell technology research and development [2] - Jindalai is also increasing its investment in Zhongke Hongtai to enter the vascular interventional surgical robot field, with products currently undergoing special review procedures for national innovative medical devices [2]

Core Viewpoint - The recent investment by Jindalai (688057.SH) in stem cell company Jici Medical has raised questions from the stock exchange regarding the reasonableness of Jici Medical's immediate revenue generation and the significant increase in transaction valuation [1] Group 1: Revenue Generation - Jici Medical, established in August 2025, reported revenues of 8.6911 million yuan and 11.2273 million yuan for 2024 and the first three quarters of 2025, respectively, primarily from patent licensing and technical services [1] - The revenue sustainability and customer concentration risk have been highlighted, with the largest customer, an affiliate named Zhendijici, contributing 89.75% of revenue in 2024 and 99.02% in the first three quarters of 2025 [1] - The company plans to reduce dependency on this major client by expanding its partnerships with other institutions in the future [1] Group 2: Valuation Concerns - The transaction valuation for Jici Medical is set at 543.5961 million yuan, significantly higher than its book net assets, primarily due to the valuation of 30 unaccounted patents using the income approach [1] - The assessment assumes that revenue from the rFib cell storage business will grow from 250 million yuan in 2026 to 5 billion yuan by 2036, with a royalty rate for the patented technology set at 17.13% [1] - The company emphasized that this valuation is lower than comparable industry cases, such as Betta Pharmaceuticals' acquisition of RepuMed, which had a static price-to-sales ratio of 989 times, while this transaction is at 62.54 times [1]